ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Impact of the ONCORAL multidisciplinary city-hospital follow-up on older patients with cancer treated with oral anticancer drugs.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe ONCORAL multidisciplinary city-hospital follow-up aims to prevent and manage Drug-related problems (DRPs). This study describes and assesses the impact of ONCORAL on relative dose intensity (RDI) at 6 months of the oral anticancer drug (OAD) in older patients.
methodsClinical information, medication, Complementary and Alternative Medicine (CAM) use and ONCORAL consultations reports were collected up to six months after initiation of OAD. For patients still treated at 6 months, RDI (ratio between the prescribed dose and the recommended dose according to Summary of Product characteristics) was calculated for each OAD. Outpatients aged ≥75 years followed in ONCORAL between February, 2016 and May, 2022 were included in this study. For patients treated with several subsequent OAD, all associated courses of ONCORAL follow-up were included.
resultsOn hundred ninety patients were included (232 follow-ups) with a mean age of 81 ± 4.7 years. Most patients were treated for hematologic malignancies (77.9%) and had a Charlson index > 5 (56.3%). Polypharmacy (≥5 daily drugs) concerned 83.7% of patients. Mean RDI was 81.9% for 146 patients who reached 6 months of OAD treatment (165 follow-ups), with a RDI ≥ 85% in 60% of cases. OAD premature discontinuations were due to adverse events (35.8%) or disease progression (35.8%). 1331 DRPs prompted the intervention of the ONCORAL team.
conclusionsDespite some dose reductions, RDI at 6 months remained satisfying for most patients, suggesting that ONCORAL improves patient care. These first results promote the development of multidisciplinary follow-up for older patients treated with OAD who are prone to DRPs.
Indexed as
Identifiers
41249605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.